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Introduction: Pathologic complete response (pCR) after neoadjuvant systemic
treatment for inoperable locally advanced breast cancer is defined as complete
microscopic disappearance of invasive cancer in both the breast and axilla in
the postoperative specimen. The aim of the study was to characterize the groups
of younger (≤ 40 years old) and older (≥ 70 years old) breast cancer patients
who achieved a pCR.
Material and methods: One hundred thirty-eight consecutive patients aged
between 30 and 78 years with locally advanced breast cancer, operated on after
neoadjuvant systemic treatment between November 2007 and June 2010, were
analyzed. In this group 9 women (6.5%) were 40 years of age or younger, and
12 patients (8.7%) were 70 years of age or older.
Results: In the younger group, pCR was achieved in 1 patient with triple nega-
tive, invasive ductal breast cancer, G3, BRCA 1 mutation, treated with cisplatin.
A near pCR was achieved in 2 other patients, with triple negative, invasive duc-
tal breast cancer, G3, treated with AT. The pCR in the breast was found in a HER2
positive patient. In older patients, pCR was achieved in 2 patients with triple
negative, invasive ductal breast cancer, G3, treated with AT or FEC. Pathologic
complete response in the axilla was achieved in 1 patient with triple negative,
ductal carcinoma. The pCR rates were significantly higher in triple negative breast
cancer in both groups (p = 0.047 and p = 0.018, respectively). 
Conclusions: Pathologic complete response was significantly associated with
receptor- based subtypes in both young and old women. 
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Introduction
Pathological complete response (pCR) after neoadjuvant systemic treat-
ment for inoperable locally advanced breast cancer with intent to change
tumour status to operable or allowing reduction of its size, permitting
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breast conservation, is defined as complete micro-
scopic disappearance of invasive cancer in both the
breast and axilla in the postoperative specimen 
[1, 2]. The sequence of neoadjuvant systemic treat-
ment and subsequent operation provides a unique
opportunity to objectively determine in vivo cancer
response to preoperative chemo- or endocrine ther-
apy [1, 3]. The pCR predicts better survival, where-
as a large residual cancer burden worsens disease-
free survival prognosis [4, 5]. The age of the patient
at diagnosis may influence these parameters [6-8]. 
The aim of our study was to characterize a group
of younger (≤ 40 years) and older (≥ 70 years)
breast cancer patients who achieved a pCR after
neoadjuvant systemic treatment.
Material and methods
The Breast Cancer Database in the Departments
of Chemotherapy, Proliferative Diseases and Surgi-
cal Oncology, Copernicus Memorial Hospital, Can-
cer Centre, Lodz, Poland was searched, and a con-
secutive series of 138 patients identified who had
inoperable locally advanced breast cancer or
resectable tumours suitable for downstaging, and
treated with neoadjuvant chemo- or endocrine ther-
apy then subsequently resected between Novem-
ber 2007 and June 2010. 
Inclusion criteria
Breast cancer patients who had preoperative sys-
temic therapy, 40 years of age or younger or 70
years of age or older, treated between November
2007 and June 2010, were included.
Before starting neoadjuvant systemic treatment,
a diagnosis of invasive breast cancer was confirmed
by core-needle biopsy of the breast tumour,
although in some cases only results of fine needle
aspiration with oestrogen (ER) and progesterone
receptor (PR) concentrations were available. Dedi-
cated breast pathologists from the Department of
Pathology, Medical University of Lodz, reviewed all
biopsy specimens. The ER and PR status was deter-
mined by immunohistochemistry (IHC) using the
Allred score. Human epidermal growth factor recep-
tor 2 (HER2) status was evaluated by immunohis-
tochemistry or by fluorescence in situ hybridization.
HER2-positive tumours were defined as 3+ recep-
tor overexpression on IHC staining and/or gene
amplification found on fluorescent in situ hybridiza-
tion. TNM clinical staging was assessed by mam-
mography, ultrasound of the breast, axilla and
abdomen, and chest X-ray. In selected cases, 
MRI of the breast was performed. The following pre-
operative chemo- and endocrine therapy regimens
were used: AT (doxorubicin 50 mg/m2, docetaxel
75 mg/m2), FAC (5-fluorouracil 500 mg/m2, dox-
orubicin 50 mg/m2, cyclophosphamide 500 mg/m2),
FEC (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2,
cyclophosphamide 500 mg/m2), AC (doxorubi-
cin 60 mg/m2, cyclophosphamide 600 mg/m2), 
EC (epirubicin 100 mg/m2, cyclophosphamide
600 mg/m2), TAC (docetaxel 75 mg/m2, doxorubicin
50 mg/m2, cyclophosphamide 500 mg/m2), cisplatin
(75 mg/m2), CMF (cyclophosphamide 100 mg/m2,
methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2),
and anastrozole. The various regimens were in 
21-day cycles, except for 28-day CMF cycles. Anas-
trozole was taken orally 1 mg daily. Upon comple-
tion of chemotherapy (4-6 cycles), dedicated breast
surgeons performed mastectomy or breast con-
servation, with axillary dissection or sentinel node
biopsy. Postoperative specimens were examined by
dedicated breast pathologists. pCR was defined as
postoperative microscopic absence of invasive car-
cinoma in breast tissue, and axillary lymph nodes
after neoadjuvant systemic treatment. A near com-
plete response with only minimal residual disease
was described as scattered tumour cells in the pri-
mary tumour site or lymph node or minimal cellu-
larity in the surgical specimen. pCR and near pCR
were key points in statistical analysis.
As these procedures were routine diagnosis and
treatment; ethical approval and informed consent
were not required.
Statistical analysis 
The computer package Statistica version 8.0
(StatSoft) was used for all statistical analyses. The
two-tailed Fisher’s exact test was used to compare
variables with a p value of 0.05 established as the
threshold of statistical significance.
Results
Young age group
Of 138 consecutive patients from our database,
9 women (6.5%) were between 30 and 40 years old,
mean age 36.3 years, all with invasive ductal breast
cancer; grade G2 – 2 patients, G3 – 6 patients, Gx
– 1 patient; stage IIB - 1 patient, IIIA – 5 patients,
IIIB – 2 patients, IIIC – 1 patient; ER(0)PR(0)HER2(0)
(triple negative) – 4 patients, ER(+)PR(+)HER2(0) –
2 patients, ER(+)PR(+)HER2(+) – 2 patients,
ER(0)PR(0)HER2(+) – 1 patient. Neoadjuvant regi-
mens comprised: AT – 6 patients, TAC – 1 patient,
AC – 1 patient, cisplatin – 1 patient. After comple-
tion of neoadjuvant chemotherapy, mastectomy
was performed in 8 patients, and breast conser-
vation in 1 patient. The pCR was achieved in 
1 patient from this younger patient group (1/9,
fraction = 0.11), with triple negative, invasive duc-
tal breast cancer, G3, BRCA1 mutation, treated with
cisplatin. Furthermore, a near complete response
to preoperative chemotherapy was achieved in 
2 other patients. These also had triple negative,
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invasive ductal breast cancers, G3, treated with
AT. One of these had a pCR in the axilla but scat-
tered 2 mm cancer cells in the breast, in the mas-
tectomy specimen. In the other, pCR was achieved
in the breast but a 3 mm metastasis remained in
the axillary lymph node after breast conservation.
Additionally, pCR in the breast was found in
a HER2 positive breast cancer patient, treated with
AT. The characteristics of these young (≤ 40 years
old) patients are shown in Table IA and II. Com-
parison of pCR according to receptor-based sub-
types and grade with p values is summarized in
Table III.
Older age group
Of 138 consecutive patients from our database,
12 (8.7%) were between 70 and 78 years old, mean
age 72.3. Histopathological tumour type: invasive
ductal carcinoma (9 patients), invasive lobular 
classical type (1 patient), invasive lobular pleomor-
phic type mixed with 5% invasive ductal cancer 
(1 patient), mucinous cancer (1 patient). Tumour
grade: there were 1, 3 and 8 patients with grades
Gx, G2 and G3, respectively. Tumour staging: stage
IIA (1 patient), IIIA (4 patients), IIIB (6 patients), 
IIIC (1 patient). Receptors: ER(+)PR(+)HER2(0) in 
4 patients, ER(0)PR(0)HER2(0) (triple negative) 
in 4 patients, ER(0)PR(+)HER2(0) in 1 patient,
ER(+)PR(+)HER2-ambiguous in 1 patient, ER(0)PR(0)
HER2(+) in 1 patient, ER(+)PR(0)HER2(+) in 1 patient.
The following neoadjuvant chemotherapy regimens
were used: AT – 4 patients, FEC – 4 patients, 
FAC – 1 patient, CMF – 1 patient, EC – 1 patient; 
in 1 patient neoadjuvant endocrine therapy (anas-
trozole) was used. After completion of systemic
therapy, mastectomy with axillary dissection was
performed in all patients. pCR was achieved by AT
or FEC in 2 patients (2/12; fraction = 0.16) with triple
negative, invasive G3 ductal cancer. Additionally,
pCR in the axilla was achieved with neoadjuvant
FAC in 1 other patient with triple negative, G3 inva-
sive ductal cancer. Characteristics of the older (≥ 70
years old) breast cancer patient group are shown
in Table I B and II. Comparison of pCR according to
receptor-based subtypes, grade and histopatho-
logical tumour type with p values is summarized in
Table III. 
In both young and old groups, higher rates of
pCR were observed in patients with triple negative
receptor status (p = 0.047 and p = 0.018, respec-
tively; Table III). No statistical differences were found
in terms of ER, PR, or HER2 receptor status in both
groups (Table III). The tumour grade showed no sta-
tistically significant influence on pCR both in young
and old patients (p = 0.46 and p = 0.49). In women
aged 70 years and above, no differences in pCR
were shown in terms of histopathological cancer
type (p = 0.5; Table III). 
Patient Age Cancer ER PR HER2G cTN ypTN CHT Surgery BRCA  pCR
[years] type mutation
1 30 Inv ductal  0 0 + G3 cT4N3 ypT2N3 TAC Mastectomy No No
2 35 Inv ductal 0 0 0 G3 cT4N2 ypT1aN0 AT Mastectomy No Very good
(scattered response
2 mm cancer  (near pCR)
cells in breast)
3 35 Inv ductal + + 0 G3 cT2N2 ypT1cN1 AC Mastectomy No No
4 36 Inv ductal + + + Gx cT2N2 ypT1cN2a AT Mastectomy No No
5 36 Inv ductal + + 0 G2 cT3N2 ypT1cN1a AT Mastectomy No No
6 37 Inv ductal  0 0 0 G3 cT2N2 ypT0N0 Cis- Mastectomy Yes pCR
platin
7 39 Inv ductal  + + + G2 cT3N2 ypT0N2 AT Mastectomy No pCR in breast 
8 39 Inv ductal  0 0 0 G3 cT2N1 ypT0N1 AT BCT No Very good
(scattered response
3 mm cancer  (near pCR)
cells in one 
axillary node)




Inv ductal – invasive ductal, G – grading, cTN – clinical staging (tumour and nodes), ypTN – pathological staging (tumour and nodes), 
CHT – chemotherapy, BCT – breast conserving therapy, pCR – pathological complete response
Table I A. Pathological response after neoadjuvant chemotherapy in younger breast cancer patients (≤ 40 years old)
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Discussion 
Scientific studies have shown that age of breast
cancer patients is inversely related to tumour
aggressiveness and outcome [6-9]. Both age groups
younger than 40 years and older than 70 years are
outside the upper and lower age limits in screen-
ing programmes in the majority of countries in the
world [9]. We have therefore focused attention on
patients in both of these age groups, and in par-
ticular with respect to pathological remission after
neoadjuvant systemic treatment. Several articles
have shown that the highest rate of pCR occurs in
triple negative and HER2 positive breast cancer sub-
types in comparison with ER(+) tumours, but no
age stratification has been demonstrated [10-13].
Consistently, in our study pCR or a near complete
pathological response to neoadjuvant chemother-
apy was achieved in the younger cohort of patients
in triple negative breast cancer, which was statis-
tically significant (p = 0.047), and pCR solely in the
breast in an HER2 positive tumour. Similarly, in the
older age group (≥ 70 years old) we observed pCR
and pCR in the axilla in the triple negative breast
cancer subtype (p = 0.018). Indeed, surgeons from
the Netherlands Cancer Institute have stated that
among various variables such as menopausal sta-
tus, tumour stage, nodal involvement, and histol-
ogy, the receptor-based subtype was the only sig-
nificant predictor of pCR, with triple negative
patients being more chemosensitive [10]. Recently
a new surrogate, the residual cancer burden (RCB),
has been proposed to measure chemosensitivity as
a continuous variable derived from the primary
tumour dimensions, cellularity of the tumour bed,
and axillary nodal burden. The RCB is a significant
predictor of distant relapse-free survival and can
be used to more precisely determine the response
to chemotherapy [11]. Peintinger et al. have stated
that minimal residual disease (RCB-I) carries com-
parable prognosis as pCR (RCB-0) [5]. In contrast,
extensive residual disease (RCB-III) is associated
with poor prognosis [5, 10-12]. In view of the small
sample size, in our study pCR and near pCR were
combined in the statistical analysis. This can be jus-
tified in the light of research conducted by pathol-
ogists, surgical oncologists, medical oncologists and
biologists from the University of Texas M.D. Ander-
son Cancer Center and Vall d’Hebron University
Hospital, Barcelona [5, 10-12].  
Age Cancer ER PR HER2G cTN ypTN CHT Surgery pCR
[years] type
P1 70 Inv ductal + + 0 G2 cT4N2 ypT2mN1 AT Mastectomy No
P2 70 Inv ductal + + amb Gx cT4N1 ypT2N3 FEC Mastectomy No
P3 70 Inv ductal 0 0 0 G3 cT4N1 ypT2N0 FAC Mastectomy pCR in axilla 
P4 70 Inv ductal + + 0 G2 cT3N1 ypT2N1 AT Mastectomy No
P5 71 Inv ductal 0 0 0 G3 cT3N1 ypT0N0 FEC Mastectomy pCR
P6 71 Inv ductal 0 0 0 G3 cT2N0 ypT2N1 CMF Mastectomy Progression
P7 71 Inv ductal 0 0 0 G3 cT4N1 ypT0N0 AT Mastectomy pCR
P8 73 Inv lobular + + 0 G3 cT4N2 ypT3N3 AT Mastectomy No
P9 73 Inv ductal + + 0 G2 cT3N1 ypT2N1 EC Mastectomy No
P10 74 Pleom. 0 0 + G3 cT4N2 ypT3N2 FEC Mastectomy No
lobular 95%,
inv ductal 5%
P11 77 Inv ductal 0 + 0 G3 cT3N2 ypT1N2b Anastrozole Mastectomy No
P12 78 Mucinous + 0 + G3 cT2N3 ypT2N2 FEC Mastectomy No
Inv ductal – invasive ductal, Inv lobular – invasive lobular, Pleom. lobular – pleomorphic lobular, amb – ambiguous, G – grading, cTN – clinical
staging (tumour and nodes), ypTN – pathological staging (tumour and nodes), CHT – chemotherapy, pCR – pathological complete response
Table I B. Pathological response after neoadjuvant chemo- and endocrine therapy in older breast cancer patients 
(≥ 70 years old)
Parameter ≤ 40 years ≥ 70 years 
Age (mean ± SD) 36.3 ±3.0 72.3 ±2.8
Cancer type  9/0 9/3
(ductal/other types) 
ER (positive/negative) 4/5 6/6
PR (positive/negative) 4/5 6/6
HER2 (positive/negative) 3/9 3/9
Triple negative vs. ER, PR  4/5 4/8
and/or HER2 positive
G (G3/G2 or Gx) 6/3 8/4
pCR/no pCR 3/6 3/9
Table II. Summary characteristics of the two study
groups314 Arch Med Sci 2, April / 2012
With respect to histological subtypes, it has pre-
viously been demonstrated that the pCR rate after
primary chemotherapy is significantly lower in inva-
sive lobular carcinoma, frequently characterized by
high expression of steroid hormone receptors, when
compared with the invasive ductal histotype [3, 13].
In our cohort of patients, both younger (≤ 40 years
old) and older (≥ 70 years old), pCR in the breast
and/or in the axilla was achieved in patients with
invasive ductal breast cancer, which is in accordance
with the literature [3]. 
Measures of high cell proliferation such as high
grade also correlate with good response to neoad-
juvant chemotherapy [14, 15]. In our study, all
younger and older patients who achieved pCR or
good partial response had G3 tumours. Our previ-
ous research on the characteristics of 101 breast
cancer patients across the complete age range 
(30-78 years, median: 56.1 years), treated in our
institution, also showed the highest rate of pCR in
triple negative breast cancer patients, G3, with inva-
sive ductal carcinoma [16]. These results mirror the
characteristics of younger (≤ 40 years old) and old-
er (≥ 70 years old) age groups in the present arti-
cle. Although published breast cancer models strat-
ified by age have shown disparities between
younger and older women, with more favourable
tumour biology in the latter [6, 7], the association
of receptor-based subtypes (triple negative) with
pCR rates was comparable in both age groups in
our study. However, in view of the small sample
size, we plan to study a more extensive cohort with
special emphasis on the impact of pCR on survival
in young and elderly patients. This is particularly
important because, despite the highest rate of pCR
in triple negative and HER2 positive tumours, those
with residual disease after neoadjuvant systemic
treatment carry the worst overall survival, with
a high relapse rate [17, 18]. One of the studied
patients from the younger group, aged 40 years,
with triple negative breast cancer, with a large resid-
ual tumour burden after completion of chemother-
apy (AT) and mastectomy, developed massive lung
metastases 3 months later (Table I). In view of this
observation, it is vital to differentiate triple nega-
tive breast cancer patients with defective DNA
repair similar to BRCA1-associated tumours that are
sensitive to anthracyclines and resistant to taxane-
based chemotherapy [19, 20].
In conclusion, we have concluded that pCR was
significantly linked to receptor-based subtype in
both young (≤ 40 years) and old (≥ 70 years)
women. pCR rates were statistically significantly
higher in triple negative breast cancer in both
groups. Further studies are needed to incorporate
multigene signatures within the receptor-based
classification to predict chemosensitivity in the
adjuvant setting [21] and to design targeted ther-
apies in the genomic and proteomic era [22-24].  
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